Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Assets (2016 - 2025)

Historic Assets for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $903000.0.

  • Guided Therapeutics' Assets fell 2770.22% to $903000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $903000.0, marking a year-over-year decrease of 2770.22%. This contributed to the annual value of $1.4 million for FY2024, which is 1743.56% down from last year.
  • Per Guided Therapeutics' latest filing, its Assets stood at $903000.0 for Q3 2025, which was down 2770.22% from $940000.0 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Assets ranged from a high of $3.9 million in Q3 2022 and a low of $903000.0 during Q3 2025
  • Its 5-year average for Assets is $1.9 million, with a median of $1.7 million in 2021.
  • Per our database at Business Quant, Guided Therapeutics' Assets soared by 54890.11% in 2021 and then plummeted by 5151.12% in 2023.
  • Guided Therapeutics' Assets (Quarter) stood at $2.0 million in 2021, then skyrocketed by 65.0% to $3.4 million in 2022, then crashed by 50.42% to $1.7 million in 2023, then dropped by 17.44% to $1.4 million in 2024, then plummeted by 34.47% to $903000.0 in 2025.
  • Its last three reported values are $903000.0 in Q3 2025, $940000.0 for Q2 2025, and $967000.0 during Q1 2025.